141 related articles for article (PubMed ID: 2958875)
1. Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.
Salup RR; Toth JA; Hiserodt JC; Wolmark N
Prog Clin Biol Res; 1987; 244():39-48. PubMed ID: 2958875
[No Abstract] [Full Text] [Related]
2. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
Salup RR; Wiltrout RH
Cancer Res; 1986 Jul; 46(7):3358-63. PubMed ID: 3486710
[TBL] [Abstract][Full Text] [Related]
3. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
Grimm EA
Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
[No Abstract] [Full Text] [Related]
5. An approach for the generation of effector lymphocytes from tumor-bearing hosts for the adoptive immunotherapy of established tumors.
Shu SY; Chou T
Prog Clin Biol Res; 1987; 244():27-37. PubMed ID: 3498953
[No Abstract] [Full Text] [Related]
6. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
7. Cycling of immune responses to a syngeneic murine mammary adenocarcinoma.
Huber SA; Bigi G; Lucas ZJ
Cancer Res; 1980 Oct; 40(10):3484-90. PubMed ID: 6449282
[No Abstract] [Full Text] [Related]
8. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70.
Douin-Echinard V; Robbins PD; Lotze MT; Favre G; Couderc B
Adv Exp Med Biol; 1998; 451():353-7. PubMed ID: 10026896
[No Abstract] [Full Text] [Related]
9. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3647-51. PubMed ID: 9413217
[TBL] [Abstract][Full Text] [Related]
10. Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells.
Fisher B; Wolmark N; Saffer EA
Cancer Res; 1979 Dec; 39(12):4772-6. PubMed ID: 498106
[No Abstract] [Full Text] [Related]
11. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
Boyer CM; Kreider JW; Bartlett GL
Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
[TBL] [Abstract][Full Text] [Related]
12. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL
Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346
[TBL] [Abstract][Full Text] [Related]
13. Cloned helper and cytotoxic T lymphocytes as effector cells in adoptive immunotherapy of murine leukemia.
Bookman MA; Horak E; de Graaf PW
Prog Clin Biol Res; 1989; 288():141-9. PubMed ID: 2524069
[No Abstract] [Full Text] [Related]
14. Prophylaxis of graft-vs-host disease by adoptive transfer of a class II antigen-specific murine T-cell clone.
Shih CC; Truitt RL
Prog Clin Biol Res; 1987; 244():439-47. PubMed ID: 3116558
[No Abstract] [Full Text] [Related]
15. [Interleukin-2 and cancer immunotherapy].
Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
[No Abstract] [Full Text] [Related]
16. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma.
Cavallo F; Di Pierro F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Forni M; Modesti A; Forni G
Cancer Res; 1993 Nov; 53(21):5067-70. PubMed ID: 8221636
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells and tumor immunity: 1985.
Herberman RB
Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
[No Abstract] [Full Text] [Related]
18. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.
Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL
Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346
[TBL] [Abstract][Full Text] [Related]
19. Lysis of spontaneous murine breast tumors by human interleukin 2-stimulated syngeneic T-lymphocytes.
Merluzzi VJ; Savage DM; Souza L; Boone T; Mertelsmann R; Welte K; Last-Barney K
Cancer Res; 1985 Jan; 45(1):203-6. PubMed ID: 3871172
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2.
Mulé JJ; Rosenberg SA
Prog Clin Biol Res; 1987; 244():79-91. PubMed ID: 3310006
[No Abstract] [Full Text] [Related]
[Next] [New Search]
